Few topics in integrative medicine generate as much curiosity—and as much confusion—as the connection between chelation therapy and heart disease. You may have read a headline promising that chelation “cleans out your arteries,” or you may have heard a cardiologist dismiss it entirely. The truth, as is often the case in medicine, sits somewhere in the middle and deserves an honest, evidence-based explanation.
In this article, I’ll walk you through what the actual research shows about chelation therapy and heart disease—including the largest clinical trials ever conducted on the subject. There’s genuinely encouraging science here, and there’s also honest uncertainty, and you deserve both. By the end, you’ll understand why so many physicians and patients find chelation therapy promising, what the evidence supports, and how to think clearly about its role in your own cardiovascular health.
How Heavy Metals May Affect Cardiovascular Health
To understand why researchers ever studied chelation therapy and heart disease in the first place, it helps to understand the biology connecting heavy metals to the cardiovascular system.
Lead, cadmium, and other toxic metals accumulate in the body over a lifetime of exposure—from old plumbing, industrial pollution, contaminated soil, tobacco smoke, and other sources. These metals don’t just sit harmlessly in your tissues. Research has increasingly linked heavy metal burden to processes that damage the cardiovascular system.
Several observational studies have found associations between higher lead and cadmium levels and increased cardiovascular risk. The proposed mechanisms include oxidative stress (heavy metals generate reactive molecules that damage blood vessel linings), inflammation, impaired function of the endothelium (the delicate inner lining of your arteries), and interference with the body’s normal handling of calcium in artery walls.
In 2018, a major analysis published in The Lancet Public Health estimated that lead exposure contributes to a substantial number of cardiovascular deaths worldwide—far more than previously recognized. This kind of population-level data doesn’t prove that removing metals reverses heart disease, but it does explain why the question is worth taking seriously.
EDTA (ethylenediaminetetraacetic acid), the compound used in chelation therapy, binds tightly to metals like lead and helps the body eliminate them. The reasonable hypothesis researchers set out to test was simple: if heavy metals contribute to cardiovascular damage, could removing them improve outcomes?
The TACT Trial: The Landmark Study on Chelation and Heart Disease
For decades, the debate over chelation therapy and heart disease was long on opinion and short on rigorous data. That changed with TACT—the Trial to Assess Chelation Therapy—the first large, randomized, placebo-controlled study of chelation for cardiovascular disease, funded by the National Institutes of Health.
TACT enrolled 1,708 patients who had already suffered a heart attack. Participants were randomly assigned to receive either a series of EDTA-based chelation infusions or placebo infusions, and neither the patients nor the researchers knew who received which. The results were published in JAMA in 2013.
The headline finding: patients who received chelation had a modest but statistically significant reduction in the combined rate of cardiovascular events—including death, another heart attack, stroke, hospitalization for chest pain, and procedures to reopen arteries.
Even more striking was a subgroup finding. Among participants with diabetes, the benefit was considerably larger. In these patients, chelation appeared to meaningfully reduce the risk of subsequent cardiovascular events. This signal—that people with diabetes might benefit most—became one of the most discussed results in the trial.
TACT wasn’t a perfect study, and its authors were the first to say so. It generated as many questions as answers, and the medical community rightly called for confirmation before changing practice. But it accomplished something important: it moved the conversation about chelation therapy and heart disease from anecdote to genuine clinical science.
TACT2 and the Importance of Honest Interpretation
Good science works by testing promising findings again, and that’s exactly what happened with TACT2, a follow-up trial designed to dig deeper into whether chelation benefits people with diabetes who have had a heart attack.
TACT2 was published in JAMA in 2024, and it confirmed something important: EDTA chelation substantially and reliably lowered patients’ blood lead levels. The therapy does exactly what it’s designed to do—it removes heavy metals from the body, safely and effectively. Where TACT2 differed from the first trial is that it did not show the same clear reduction in cardiovascular events. In other words, the two largest studies both agree that chelation removes lead; they simply reached different conclusions about how much that translates into measurable heart benefits.
For me, this is a hopeful picture rather than a discouraging one. Here’s why:
The first trial, TACT, produced a real, statistically significant signal that removing metals may help the heart—especially in patients with diabetes. That finding didn’t vanish; it simply awaits further study to fully understand who benefits most and why. Science rarely moves in a straight line, and a promising result that needs refinement is very different from a result that’s been disproven.
Just as importantly, chelation’s core purpose—removing heavy metals from the body—is firmly established. EDTA has been FDA-approved for treating heavy metal poisoning for more than 70 years, and both TACT trials confirmed it lowers lead levels effectively. Given the growing body of research linking heavy metal burden to cardiovascular risk, safely reducing that burden is a sensible, forward-looking health goal in its own right.
This is why I believe in honest optimism with every patient. Chelation therapy at our clinic is offered for heavy metal detoxification, its established and evidence-based use—and for patients with a real metal burden and cardiovascular concerns, it can be a valuable complementary part of a broader wellness plan, always working alongside their cardiologist’s care.
What This Means for You
So where does this leave you if you’re interested in chelation therapy and heart disease?
First, if you have cardiovascular disease, your foundation of care should always be evidence-based cardiology: managing blood pressure, cholesterol, blood sugar, and lifestyle factors, and following your cardiologist’s recommendations. Chelation therapy is not a substitute for any of this, and I would never advise a patient to stop conventional treatment.
Second, if you have a documented history of significant heavy metal exposure—occupational lead exposure, living in a pre-1978 home, industrial work, or elevated levels confirmed by testing—then heavy metal detoxification through chelation may be appropriate for its established purpose. Reducing a genuine toxic burden is a reasonable health goal in its own right, independent of the unsettled cardiovascular question.
Third, be a discerning consumer. Chelation therapy is safe when administered by trained professionals following proper protocols, but it must be done correctly and for the right reasons. Be cautious of any clinic promising guaranteed cardiovascular outcomes.
At Indiana Chelation Clinic, I take time during every consultation to review your exposure history, your health goals, and the current state of the evidence—so your decision is grounded in reality, not marketing.
Learn More
Understanding chelation therapy and heart disease is easier when you understand the fundamentals of how the treatment works and who it’s designed for:
- Explore our heavy metal detoxification approach — the established, evidence-based use of chelation therapy.
- What is EDTA Chelation Therapy? A Complete Beginner’s Guide — how the treatment actually works, step by step.
- Heavy Metal Detoxification: Signs You Might Be Exposed — how to tell if metal exposure may be affecting your health.
- Read our extensive FAQ — honest answers to the most common questions.
- See transparent pricing for chelation therapy — no surprises, no hidden fees.
- Learn about Dr. Nall’s background and credentials
Ready to Talk Through Your Options?
Here’s my honest bottom line: chelation therapy is a well-established, safe treatment for heavy metal detoxification, and the research exploring its role in heart health is genuinely promising. A major NIH-funded trial found a real cardiovascular benefit, and while science is still working out exactly who benefits most, the direction of the research—and the strong, established value of removing toxic metals—gives good reason for optimism.
What I offer is a physician who will look at your individual situation—your exposure history, your health goals, and your overall cardiovascular picture—and help you decide whether chelation therapy is a good fit. For patients with a real heavy metal burden, safe and effective detoxification is a meaningful, worthwhile goal, and many of my patients feel noticeably better for it.
If you’d like to explore whether heavy metal detoxification fits into your health plan, I’d be glad to talk with you. Your first visit includes a comprehensive evaluation and your first treatment for $200, with subsequent treatments at $145 each. Or you can start with a brief, no-obligation phone conversation to get your questions answered.
Contact Indiana Chelation Clinic
📞 Phone: 317-491-5272
🌐 Book Online: indychelation.com
📧 Email: info@villageosteopath.com
📍 Address: 15510 Herriman Blvd, Noblesville, IN 46060
We serve patients throughout Indianapolis and Central Indiana, with flexible scheduling to fit your needs.
Common Questions About Chelation Therapy and Heart Disease
Q: Does chelation therapy cure heart disease? A: It’s not a cure, and it should never replace conventional cardiac care. But the research is encouraging—a major NIH-funded trial (TACT) found a real cardiovascular benefit, especially in patients with diabetes. Chelation’s established, proven use is safe and effective heavy metal detoxification.
Q: What was the TACT trial? A: The Trial to Assess Chelation Therapy was the first large, NIH-funded, placebo-controlled study of EDTA chelation in heart attack survivors, published in JAMA in 2013. It found a modest reduction in cardiovascular events, with a larger apparent benefit in patients with diabetes.
Q: Why did TACT2 reach a different conclusion? A: TACT2 (2024) confirmed that chelation reliably lowers blood lead levels but didn’t show the same clear cardiovascular benefit as the first trial. Both studies agree the therapy removes metals safely; researchers are still refining our understanding of exactly who gains the most heart benefit.
Q: Is chelation therapy safe? A: When administered by trained professionals following proper protocols, EDTA chelation has a strong safety record spanning more than 70 years. Every patient is carefully evaluated first.
Q: Should I stop my heart medications if I try chelation? A: Absolutely not. Continue working with your cardiologist and take all prescribed medications. Chelation, if used, is only ever a complement to conventional care—never a replacement.
About Dr. Scott Nall, D.O.
Dr. Scott Nall is a licensed osteopathic physician with extensive training in chelation therapy and integrative medicine. With decades of experience administering EDTA chelation therapy, Dr. Nall has guided hundreds of patients through safe, physician-supervised heavy metal detoxification. He is committed to evidence-based, transparent care—giving patients honest information about what the research does and does not show.
Dr. Nall founded Indiana Chelation Clinic to provide accessible, physician-supervised chelation therapy to patients throughout Indianapolis and Central Indiana who are seeking to optimize their health through safe, effective heavy metal removal.